论文部分内容阅读
目的观察重组人血管内皮抑素(恩度)联合化学治疗(化疗)注射液治疗复治中晚期(ⅢA、ⅢB、Ⅳ期)非小细胞肺癌(non small cell lung cancer,NSCLC)的临床疗效及不良反应。方法 32例经病理组织学或细胞学确诊的复治中晚期非小细胞肺癌患者,接受恩度注射液联合化疗治疗。15 mg恩度注射液中加入生理盐水500ml,匀速静脉滴注3～4 h,连续给药14 d。同时联合三代含铂化疗方案,21 d为1个周期。评价疗效及不良反应。结果 32例患者中,可评价近期疗效者30例,远期疗效者24例。可评价近期疗效的30例患者中,获得CR者0例,PR者15例,NC者11例,PD者4例;客观有效率为50%,临床获益率为86.67%。不良反应主要与化疗药物有关,也包括与恩度有关的心脏毒性。结论恩度注射液联合化疗治疗复治中晚期非小细胞肺癌,有效率得到一定程度提高,安全性好;但治疗过程中,应警惕心脏不良反应的发生。
Objective To observe the clinical efficacy of recombinant human endostatin combined with chemotherapy in the treatment of non small cell lung cancer (ⅢA, ⅢB, Ⅳ) Adverse reactions. Methods Thirty - two patients with moderate and advanced non - small cell lung cancer diagnosed by histopathology or cytology were enrolled in Ende injection combined with chemotherapy. 15 mg Ende injection of saline 500ml, uniform intravenous infusion of 3 ~ 4 h, continuous administration of 14 d. Combined with three generations of platinum-containing chemotherapy, 21 d for a cycle. Evaluation of efficacy and adverse reactions. Results Among the 32 patients, 30 patients with short-term efficacy and 24 patients with long-term efficacy could be evaluated. Among the 30 patients who could evaluate the recent efficacy, 0 were CR, 15 were PR, 11 were NC, and 4 were PD. The objective response rate was 50% and the clinical benefit rate was 86.67%. Adverse reactions are mainly associated with chemotherapeutic drugs, including cardiac toxicity associated with Endostar. Conclusion Endood injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer, the effective rate has been improved to some extent, good safety; but the course of treatment, should be alert to the occurrence of adverse cardiac reactions.